Annual Meeting 2015: Nivolumab Extends Survival for Patients With the Most Common Lung Cancer - 101271

Spotlight
Video

Annual Meeting 2015: Nivolumab Extends Survival for Patients With the Most Common Lung Cancer

EMJ has 458 videos Subscribe Here

Loading........
Description: Findings from a randomised phase III study indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC). Among patients with advanced disease that worsened after receiving platinum-based chemotherapy, those treated with nivolumab lived on average three months longer than those treated with docetaxel chemotherapy.

Presented at ASCO 2015, Chicago, IL by Professor Luis Paz-Ares, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 05/31/15
Added : 3 years ago



Recommended

More From EMJ

Nothing found.